Francesco Spinazzola
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Francesco Spinazzola has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Emanuele Nicastri
National Institute for Infectious Diseases “Lazzaro Spallanzani” IRCCS, Rome, Italy
1 shared publication - Maria Grazia Paglia
Lazzaro Spallanzani" National Institute for Infectious Diseases IRCCS , Rome, Italy
1 shared publication - Michele De Marco
National Institute for Infectious Diseases IRCCS L. Spallanzani Rome Italy
1 shared publication - Pasquale Narciso
National Institute of Infectious Diseases, Rome, Italy
1 shared publication - Piero Ghirga
National Institute for Infectious Diseases IRCCS L. Spallanzani Rome Italy
1 shared publication - Silvia Pittalis
National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, 00149 Rome, Italy
1 shared publication
Latest Publications
- Open Access
- 18 December 2006
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 6 (1) , 177
Leishmania infantumleishmaniasis in corticosteroid – treated patients
Background: The number of leishmaniasis cases associated with immunosuppression has increased regularly over the past 20 years. Immunosuppression related to HIV infection, immunosuppressive treatment, organ transplantation, and neoplastic diseases increases the risk for Leishmania-infected people to develop visceral illness. Case presentation: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. Conclusion: Physicians should recognise CS-treated patients as a population likely to be immunesuppressed. In immunodeficiency conditions, unusual forms of leishmaniasis can develop and foster the risk of a diagnostic delay and of poor response to therapy.
- 18 December 2006
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 6 (1) , 177
Open AccessLeishmania infantumleishmaniasis in corticosteroid – treated patients
Background: The number of leishmaniasis cases associated with immunosuppression has increased regularly over the past 20 years. Immunosuppression related to HIV infection, immunosuppressive treatment, organ transplantation, and neoplastic diseases increases the risk for Leishmania-infected people to develop visceral illness. Case presentation: Three cases of Leishmania infantum leishmaniasis in corticosteroid (CS)-treated patients are reported: an isolated lingual leishmaniasis in a farmer treated with CS for asthma, a severe visceral leishmaniasis associated with cutaneous lesions in a woman with myasthenia gravis, and a visceral involvement after cutaneous leishmaniasis in a man receiving CS. Conclusion: Physicians should recognise CS-treated patients as a population likely to be immunesuppressed. In immunodeficiency conditions, unusual forms of leishmaniasis can develop and foster the risk of a diagnostic delay and of poor response to therapy.